Ranjit Akolekar

List of Publications by Year
in descending order

198 papers	13,612 citations	30047 54 h-index	24961 109 g-index
209 all docs	209 docs citations	209 times ranked	9027 citing authors

#	Article	IF	Citations
1	Fetal fraction of cell free DNA in screening for hypertensive disorders at 11â€“13 weeks. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 5363-5368.	0.7	5
2	Kiellandâ€™s rotational forceps delivery: comparison of maternal and neonatal outcomes with pregnancies delivering by non-rotational forceps. Journal of Obstetrics and Gynaecology, 2022, 42, 379-384.	0.4	2
3	Secondâ€trimester contingent screening for smallâ€forâ€gestationalâ€age neonate. Ultrasound in Obstetrics and Gynecology, 2022, 59, 177-184.	0.9	12
4	<scp>STATIN</scp> trial: predictive performance of competingâ€risks model in screening for preâ€eclampsia at 35â€“37â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 69-75.	0.9	15
5	Development and validation of model for prediction of placental dysfunctionâ€related stillbirth from maternal factors, fetal weight and uterine artery Doppler at midâ€gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 61-68.	0.9	13
6	Risk of fetal loss after chorionic villus sampling in twin pregnancy derived from propensity score matching analysis. Ultrasound in Obstetrics and Gynecology, 2022, 59, 162-168.	0.9	9
7	Predictive performance for placental dysfunction related stillbirth of the competing risks model for smallâ€forâ€gestationalâ€age fetuses. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1530-1537.	1.1	11
8	Maternal race and preâ€eclampsia: Cohort study and systematic review with metaâ€analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 2082-2093.	1.1	8
9	Maternal Race and Stillbirth: Cohort Study and Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3452.	1.0	6
10	Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. American Journal of Obstetrics and Gynecology, 2021, 224, 86.e1-86.e19.	0.7	50
11	Perinatal outcome of pregnancies with prenatal diagnosis of vasa previa: systematic review and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2021, 57, 710-719.	0.9	29
12	Evaluation of the RCOG guideline for the prediction of neonates that are small for gestational age and comparison with the competing risks model. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 2110-2115.	1.1	15
13	Cellâ€free <scp>DNA</scp> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10â€“14â€‰weeks and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2021, 58, 178-189.	0.9	28
14	Fetal loss after chorionic villus sampling in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2021, 58, 48-55.	0.9	9
15	Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation, 2021, 144, 670-679.	1.6	61
16	Reference Ranges for Pulsed-Wave Doppler of the Fetal Cardiac Inflow and Outflow Tracts from 13 to 36ÂWeeksâ€™ Gestation. Journal of the American Society of Echocardiography, 2021, 34, 1007-1016.e10.	1.2	9
17	Estimated fetal weight at midâ€gestation in prediction of preâ€eclampsia in singleton pregnancies. Ultrasound in Obstetrics and Gynecology, 2021, , .	0.9	0
18	Value of routine ultrasound examination at 35â€“37â€‰weeks' gestation in diagnosis of nonâ€cephalic presentation. Ultrasound in Obstetrics and Gynecology, 2020, 55, 248-256.	0.9	19

#	Article	IF	Citations
19	Comparison of different methods of measuring angle of progression in prediction of labor outcome. Ultrasound in Obstetrics and Gynecology, 2020, 55, 391-400.	0.9	13
20	Value of routine ultrasound examination at 35â€“37 weeks' gestation in diagnosis of fetal abnormalities. Ultrasound in Obstetrics and Gynecology, 2020, 55, 75-80.	0.9	59
21	Diagnosis of major heart defects by routine firstâ€trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus. Ultrasound in Obstetrics and Gynecology, 2020, 55, 637-644.	0.9	55
22	Impact of prospective measurement of outflow tracts inÂprediction of coarctation of the aorta. Ultrasound in Obstetrics and Gynecology, 2020, 56, 850-856.	0.9	19
23	Diagnosis of fetal defects in twin pregnancies at routine 11â€“13â€week ultrasound examination. Ultrasound in Obstetrics and Gynecology, 2020, 55, 474-481.	0.9	24
24	Prevention of stillbirth: impact of twoâ€stage screening for vasa previa. Ultrasound in Obstetrics and Gynecology, 2020, 55, 605-612.	0.9	32
25	Kiellandâ€™s rotational forceps delivery: A comparison of maternal and neonatal outcomes with rotational ventouse or second stage caesarean section deliveries. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 254, 175-180.	0.5	5
26	Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. American Journal of Obstetrics and Gynecology, 2020, 223, 246.e1-246.e10.	0.7	17
27	Reply. Ultrasound in Obstetrics and Gynecology, 2020, 56, 953-954.	0.9	0
28	Maternal and Neonatal Complications of Fetal Macrosomia: Systematic Review and Meta-analysis. Obstetrical and Gynecological Survey, 2020, 75, 148-149.	0.2	0
29	Risk of Miscarriage Following Amniocentesis or Chorionic Villus Sampling: Systematic Review of Literature and Updated Meta-analysis. Obstetrical and Gynecological Survey, 2020, 75, 152-154.	0.2	2
30	Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2020, 7, 1-156.	0.9	5
31	Reply. American Journal of Obstetrics and Gynecology, 2019, 221, 659.	0.7	1
32	Diagnosis of fetal nonâ€chromosomal abnormalities on routine ultrasound examination at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 468-476.	0.9	172
33	Twoâ€stage approach for prediction of smallâ€forâ€gestationalâ€age neonate and adverse perinatal outcome by routine ultrasound examination at 35â€“37â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 484-491.	0.9	27
34	Prediction of adverse perinatal outcome by serum placental growth factor and soluble fmsâ€like tyrosine kinaseâ€1 in women undergoing induction of labor. Ultrasound in Obstetrics and Gynecology, 2019, 54, 604-608.	0.9	3
35	Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 442-451.	0.9	217
36	Prediction of largeâ€forâ€gestationalâ€age neonate by routine thirdâ€trimester ultrasound. Ultrasound in Obstetrics and Gynecology, 2019, 54, 326-333.	0.9	39

#	Article	IF	Citations
37	Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2019, 53, 734-742.	0.9	108
38	Fetal intraâ€abdominal bowel dilation in prediction ofÂcomplex gastroschisis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 376-380.	0.9	9
39	Biomarkers of impaired placentation at 35â€“37â€‰weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2019, 54, 79-86.	0.9	28
40	Routine assessment of cerebroplacental ratio at 35â€“37Âweeksâ€™ gestation in the prediction of adverseÂperinatal outcome. American Journal of Obstetrics and Gynecology, 2019, 221, 65.e1-65.e18.	0.7	50
41	Routine ultrasound at 32 vs 36 weeks' gestation: prediction of smallâ€forâ€gestationalâ€age neonates. Ultrasound in Obstetrics and Gynecology, 2019, 53, 761-768.	0.9	39
42	Prediction of smallâ€forâ€gestationalâ€age neonates at 35â€“37 weeks' gestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 630-637.	0.9	18
43	Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35â€“37 weeksâ€™ gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 486.e1-486.e11.	0.7	63
44	Firstâ€trimester screening for trisomies by cfDNA testing of maternal blood in singleton and twin pregnancies: factors affecting test failure. Ultrasound in Obstetrics and Gynecology, 2019, 53, 804-809.	0.9	66
45	Procedureâ€related risk of miscarriage following chorionic villus sampling and amniocentesis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 452-457.	0.9	35
46	Maternal and neonatal complications of fetal macrosomia: cohort study. Ultrasound in Obstetrics and Gynecology, 2019, 54, 319-325.	0.9	38
47	Maternal and neonatal complications of fetal macrosomia: systematic review and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 308-318.	0.9	144
48	Social Brain Functional Maturation in Newborn Infants With and Without a Family History of Autism Spectrum Disorder. JAMA Network Open, 2019, 2, e191868.	2.8	25
49	Prediction of smallâ€forâ€gestationalâ€age neonates at 35â€“37â€‰weeks' gestation: contribution of maternal factors and growth velocity between 20 and 36â€‰weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 488-495.	0.9	29
50	Prediction of adverse perinatal outcome by cerebroplacental ratio in women undergoing induction of labor. Ultrasound in Obstetrics and Gynecology, 2019, 53, 473-480.	0.9	30
51	Impaired placental perfusion and major fetal cardiac defects. Ultrasound in Obstetrics and Gynecology, 2019, 53, 68-72.	0.9	13
52	Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. Ultrasound in Obstetrics and Gynecology, 2019, 53, 465-472.	0.9	122
53	Routine firstâ€trimester screening for fetal trisomies in twin pregnancy: cellâ€free DNA test contingent on results from combined test. Ultrasound in Obstetrics and Gynecology, 2019, 53, 208-213.	0.9	28
54	Comparison of diagnostic accuracy of early screening for preâ€eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound in Obstetrics and Gynecology, 2018, 51, 743-750.	0.9	219

#	Article	IF	Citations
55	Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. Ultrasound in Obstetrics and Gynecology, 2018, 52, 35-43.	0.9	109
56	ASPRE trial: incidence of preterm preâ€eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. Ultrasound in Obstetrics and Gynecology, 2018, 51, 738-742.	0.9	54
57	Chronic Hypertension and Adverse Pregnancy Outcome: A Cohort Study. Obstetrical and Gynecological Survey, 2018, 73, 7-8.	0.2	1
58	Fetal Medicine Foundation fetal and neonatal population weight charts. Ultrasound in Obstetrics and Gynecology, 2018, 52, 44-51.	0.9	197
59	Prediction and prevention of smallâ€forâ€gestationalâ€age neonates: evidence from SPREE and ASPRE. Ultrasound in Obstetrics and Gynecology, 2018, 52, 52-59.	0.9	91
60	Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age. Fetal Diagnosis and Therapy, 2018, 43, 250-265.	0.6	16
61	Fetal major cardiac defects and placental dysfunction at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 51, 194-198.	0.9	24
62	Reference Ranges for the Size of the Fetal Cardiac Outflow Tracts From 13 to 36 Weeks Gestation. Circulation: Cardiovascular Imaging, 2018, 11, e007575.	1.3	17
63	Screening for preâ€eclampsia by maternal factors and biomarkers at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 52, 186-195.	0.9	241
64	Risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review of the literature. Minerva Obstetrics and Gynecology, 2018, 70, 215-219.	0.5	27
65	Accuracy of competingâ€risks model in screening for preâ€eclampsia by maternal factors and biomarkers at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 751-755.	0.9	182
66	Proposed clinical management of pregnancies after combined screening for preâ€eclampsia at 35â€“37 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 50, 383-387.	0.9	27
67	Impaired placentation in women with chronic hypertension who develop preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2017, 50, 496-500.	0.9	21
68	Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound in Obstetrics and Gynecology, 2017, 50, 228-235.	0.9	112
69	Reply. Ultrasound in Obstetrics and Gynecology, 2017, 49, 666-667.	0.9	0
70	Association of chronic hypertension with birth of smallâ€forâ€gestationalâ€age neonate. Ultrasound in Obstetrics and Gynecology, 2017, 50, 361-366.	0.9	31
71	Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. Obstetric Medicine, 2017, 10, 170-173.	0.5	7
72	ASPRE trial: performance of screening for preterm preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2017, 50, 492-495.	0.9	263

#	Article	IF	Citations
73	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology, 2017, 217, 585.e1-585.e5.	0.7	136
74	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine, 2017, 377, 613-622.	13.9	1,462
75	Metabolomic determination of pathogenesis of late-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 658-664.	0.7	35
76	Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 194-200.	0.9	21
77	Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF. Ultrasound in Obstetrics and Gynecology, 2017, 49, 201-208.	0.9	19
78	Screening for preâ€eclampsia using sFltâ€1/PlGF ratio cutâ€off of 38 at 30â€“37 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 73-77.	0.9	27
79	P14â€…Significance and associations of aberrant right subclavian artery in the fetal cardiology setting. Heart, 2016, 102, A7.2-A8.	1.2	3
80	Reply. Ultrasound in Obstetrics and Gynecology, 2016, 47, 789-789.	0.9	0
81	Uterine artery pulsatility index at 30â€“34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 308-315.	0.9	24
82	Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 203-209.	0.9	55
83	Prospective firstâ€trimester screening for trisomies by cellâ€free DNA testing of maternal blood in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2016, 47, 705-711.	0.9	80
84	Endoscopic Placental Laser Coagulation in Dichorionic and Monochorionic Triplet Pregnancies. Fetal Diagnosis and Therapy, 2016, 40, 174-180.	0.6	8
85	Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19â€“24 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 624-630.	0.9	21
86	Prediction of stillbirth from placental growth factor at 11â€“13 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 618-623.	0.9	22
87	Prediction of stillbirth from maternal demographic and pregnancy characteristics. Ultrasound in Obstetrics and Gynecology, 2016, 48, 607-612.	0.9	39
88	Prediction of stillbirth from placental growth factor at 19â€“24 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 631-635.	0.9	15
89	Prediction of stillbirth from biochemical and biophysical markers at 11â€“13 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 613-617.	0.9	34
90	Clinical implementation of routine screening for fetal trisomies in the <scp>UK</scp> <scp>NHS</scp>: cellâ€free <scp>DNA</scp> test contingent on results from firstâ€trimester combined test. Ultrasound in Obstetrics and Gynecology, 2016, 47, 45-52.	0.9	108

#	Article	IF	Citations
91	Maternal and pregnancy characteristics affect plasma fibrin monomer complexes and D-dimer reference ranges for venous thromboembolism in pregnancy. American Journal of Obstetrics and Gynecology, 2016, 215, 466.e1-466.e8.	0.7	17
92	Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 194-202.	0.9	57
93	Screening for trisomies by cellâ€free DNA testing of maternal blood: consequences of a failed result. Ultrasound in Obstetrics and Gynecology, 2016, 47, 698-704.	0.9	124
94	Re: Risk of fetal loss associated with invasive testing following combined firstâ€trimester screening for Down syndrome: a national cohort of 147â€‰987 singleton pregnancies. C. B. Wulff, T. A. Gerds, L. Rode, C. K. Ekelund, O. B. Petersen, A. Tabor and the Danish Fetal Medicine Study Group. Ultrasound Obstet Gynecol 2016; 47: 38â€“44. Ultrasound in Obstetrics and Gynecology, 2016, 47, 14-14.	0.9	4
95	Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. New England Journal of Medicine, 2016, 374, 434-443.	13.9	308
96	Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. American Journal of Obstetrics and Gynecology, 2016, 214, 103.e1-103.e12.	0.7	365
97	Reply. Ultrasound in Obstetrics and Gynecology, 2015, 46, 253-254.	0.9	0
98	Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. Ultrasound in Obstetrics and Gynecology, 2015, 46, 437-445.	0.9	53
99	Reply. Ultrasound in Obstetrics and Gynecology, 2015, 45, 755-757.	0.9	2
100	Metabolomic Analysis for First Trimester Down Syndrome Prediction. Obstetric Anesthesia Digest, 2015, 35, 35-36.	0.0	0
101	Umbilical and fetal middle cerebral artery Doppler at 30â€“34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2015, 45, 409-420.	0.9	61
102	First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. Fetal Diagnosis and Therapy, 2015, 38, 14-21.	0.6	58
103	Prediction of smallâ€forâ€gestationalâ€age neonates: screening by fetal biometry at 30â€“34 weeks. Ultrasound in Obstetrics and Gynecology, 2015, 45, 551-558.	0.9	60
104	Fetal middle cerebral artery and umbilical artery pulsatility index: effects of maternal characteristics and medical history. Ultrasound in Obstetrics and Gynecology, 2015, 45, 402-408.	0.9	28
105	Competing risks model in screening for preeclampsia by maternal characteristics and medical history. American Journal of Obstetrics and Gynecology, 2015, 213, 62.e1-62.e10.	0.7	280
106	Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 30-34 weeks. Ultrasound in Obstetrics and Gynecology, 2015, 45, 707-714.	0.9	25
107	Endoscopic Placental Laser Coagulation in Monochorionic Diamniotic Twins with Type II Selective Fetal Growth Restriction. Fetal Diagnosis and Therapy, 2015, 38, 86-93.	0.6	54
108	Analysis of cellâ€free <scp>DNA</scp> in maternal blood in screening for fetal aneuploidies: updated metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2015, 45, 249-266.	0.9	547

#	Article	IF	Citations
109	Umbilical and fetal middle cerebral artery Doppler at 35â€“37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2015, 46, 82-92.	0.9	85
110	Validation of metabolomic models for prediction of early-onset preeclampsia. American Journal of Obstetrics and Gynecology, 2015, 213, 530.e1-530.e10.	0.7	51
111	Procedureâ€related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2015, 45, 16-26.	0.9	548
112	Pregnancy Loss Following Amniocentesis or CVS Samplingâ€”Time for a Reassessment of Risk. Journal of Clinical Medicine, 2014, 3, 741-746.	1.0	8
113	Biparietal diameter at 11 to 13â€‰weeks' gestation in fetuses with holoprosencephaly. Prenatal Diagnosis, 2014, 34, 134-138.	1.1	5
114	Is high fetal nuchal translucency associated with submicroscopic chromosomal abnormalities on array <scp>CGH</scp>?. Ultrasound in Obstetrics and Gynecology, 2014, 43, 620-624.	0.9	49
115	Association between reduced fetal movements at term and abnormal uterine artery Doppler indices. Ultrasound in Obstetrics and Gynecology, 2014, 43, 548-552.	0.9	27
116	First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical Testing. Fetal Diagnosis and Therapy, 2014, 35, 118-126.	0.6	108
117	Timing of birth in multiple pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 319-326.	1.4	9
118	Prenatal prediction of need for ventriculoperitoneal shunt in open spina bifida. Ultrasound in Obstetrics and Gynecology, 2014, 43, 159-164.	0.9	20
119	Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8583-8588.	3.3	233
120	Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal Abnormalities. Fetal Diagnosis and Therapy, 2014, 35, 174-184.	0.6	51
121	Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-Analysis. Fetal Diagnosis and Therapy, 2014, 35, 156-173.	0.6	132
122	A new direction for prenatal chromosome microarray testing: software-targeting for detection of clinically significant chromosome imbalance without equivocal findings. PeerJ, 2014, 2, e354.	0.9	15
123	Midbrain and Falx in Fetuses with Absent Corpus Callosum at 11â€“13 Weeks. Fetal Diagnosis and Therapy, 2013, 33, 41-46.	0.6	17
124	Maternal serum visfatin at 11â€“13 weeksâ€™ gestation in preeclampsia. Journal of Human Hypertension, 2013, 27, 261-264.	1.0	16
125	Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. Fetal Diagnosis and Therapy, 2013, 33, 8-15.	0.6	464
126	Combined Screening for Preeclampsia and Small for Gestational Age at 11Â–13 Weeks. Fetal Diagnosis and Therapy, 2013, 33, 16-27.	0.6	180

#	Article	IF	Citations
127	Maternal and Neonatal Outcomes of Successful Kielland's Rotational Forceps Delivery. Obstetrics and Gynecology, 2013, 121, 1032-1039.	1.2	40
128	Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks' Gestation. Fetal Diagnosis and Therapy, 2013, 34, 241-247.	0.6	31
129	Association between firstâ€trimester maternal serum pregnancyâ€associated plasma proteinâ€A and obstetric complications. Prenatal Diagnosis, 2013, 33, 839-847.	1.1	54
130	Asymmetric dimethylarginine, arginine and homoarginine at 11â€“13 weeksâ€™ gestation and preeclampsia: a caseâ€“control study. Journal of Human Hypertension, 2013, 27, 38-43.	1.0	54
131	Maternal serum vitamin D levels at 11â€“13 weeks of gestation in preeclampsia. Journal of Human Hypertension, 2013, 27, 115-118.	1.0	40
132	Maternal racial origin and adverse pregnancy outcome: a cohort study. Ultrasound in Obstetrics and Gynecology, 2013, 41, 278-285.	0.9	83
133	Procedure-related pregnancy loss following invasive prenatal sampling: time for a new approach to risk assessment and counseling. Expert Review of Obstetrics and Gynecology, 2013, 8, 135-142.	0.4	4
134	A Competing Risks Model in Early Screening for Preeclampsia. Fetal Diagnosis and Therapy, 2012, 32, 171-178.	0.6	182
135	Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11â€“13 weeks in preeclampsia. Journal of Human Hypertension, 2012, 26, 253-258.	1.0	13
136	Maternal serum placental growth hormone at 11â€“13 weeksâ€™ gestation in pregnancies delivering small for gestational age neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1796-1799.	0.7	15
137	Metabolomics and first-trimester prediction of early-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1840-1847.	0.7	101
138	First-trimester maternal serum vitamin D and mode of delivery. British Journal of Nutrition, 2012, 108, 1972-1975.	1.2	30
139	Maternal Serum Vitamin D at 11â€“13 Weeks in Pregnancies Delivering Small for Gestational Age Neonates. Fetal Diagnosis and Therapy, 2012, 31, 103-108.	0.6	25
140	Multiplex ligation-dependent probe amplification (MLPA): a reliable alternative for fetal chromosome analysis?. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1383-1386.	0.7	7
141	Maternal Hemodynamics at 11â€“13 Weeksâ€™ Gestation in Gestational Diabetes Mellitus. Fetal Diagnosis and Therapy, 2012, 31, 216-220.	0.6	20
142	Maternal Hemodynamics at 11Â–13 Weeks of Gestation in Pregnancies Delivering Small for Gestational Age Neonates. Fetal Diagnosis and Therapy, 2012, 32, 231-238.	0.6	25
143	Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2012, 31, 87-93.	0.6	54
144	OS084. Maternal haemodynamics at 11â€“13 weeks of gestation and adverse pregnancy outcomes. Pregnancy Hypertension, 2012, 2, 223-224.	0.6	2

#	Article	IF	Citations
145	Maternal Hemodynamics in Normal Pregnancies at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2012, 32, 179-185.	0.6	19
146	Maternal hemodynamics at 11â€“13 weeks' gestation and risk of preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2012, 40, 28-34.	0.9	76
147	Criteria for Screening and Diagnosis of Gestational Diabetes Mellitus in the First Trimester of Pregnancy. Fetal Diagnosis and Therapy, 2011, 30, 108-115.	0.6	42
148	Prediction of Small-for-Gestation Neonates from Biophysical and Biochemical Markers at 11â€“13 Weeks. Fetal Diagnosis and Therapy, 2011, 29, 148-154.	0.6	153
149	First trimester maternal uterine artery Doppler examination in HIV-positive women. HIV Medicine, 2011, 12, 632-636.	1.0	3
150	Maternal serum 25-hydroxyvitamin D levels at 11+0-13+6â€fweeks in pregnant women with diabetes mellitus and in those with macrosomic neonates. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 951-955.	1.1	30
151	Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing. PLoS ONE, 2011, 6, e21791.	1.1	243
152	Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenatal Diagnosis, 2011, 31, 135-141.	1.1	187
153	Prediction of miscarriage and stillbirth at 11â€“13 weeks and the contribution of chorionic villus sampling. Prenatal Diagnosis, 2011, 31, 38-45.	1.1	81
154	Prediction of early, intermediate and late preâ€eclampsia from maternal factors, biophysical and biochemical markers at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 66-74.	1.1	377
155	Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 75-83.	1.1	101
156	Maternal serum insulinâ€like growth factorâ€binding proteinâ€1 (IGFBPâ€1) at 11â€“13 weeks in preâ€eclampsia. Prenatal Diagnosis, 2011, 31, 196-201.	1.1	12
157	Maternal serum adiponectin at 11 to 13 weeks of gestation in the prediction of macrosomia. Prenatal Diagnosis, 2011, 31, 479-483.	1.1	34
158	Adrenal gland length in euploid and trisomy 18 fetuses at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 773-777.	1.1	3
159	Fetal RHD genotype detection from circulating cellâ€free fetal DNA in maternal plasma in nonâ€sensitized RhD negative women. Prenatal Diagnosis, 2011, 31, 802-808.	1.1	57
160	Association of placental volume measured by MRI and birth weight percentile. Journal of Magnetic Resonance Imaging, 2011, 34, 1125-1130.	1.9	38
161	Maternal Serum Adiponectin at 11â€“13 Weeks of Gestation in Preeclampsia. Fetal Diagnosis and Therapy, 2011, 29, 208-215.	0.6	24
162	Maternal Serum Visfatin at 11â€“13 Weeks of Gestation in Gestational Diabetes Mellitus. Clinical Chemistry, 2011, 57, 609-613.	1.5	78

#	Article	IF	Citations
163	Maternal Serum Adiponectin at 11â€“13 Weeks of Gestation in Pregnancies Delivering Small for Gestation Neonates. Fetal Diagnosis and Therapy, 2011, 29, 274-279.	0.6	5
164	Contribution of Method of Conception on Pregnancy Outcome after the 11â€“13 Weeks Scan. Fetal Diagnosis and Therapy, 2011, 30, 9-22.	0.6	32
165	Maternal Serum Progesterone-Induced Blocking Factor at 11â€“13 Weeksâ€™ Gestation in Spontaneous Early Preterm Delivery. Fetal Diagnosis and Therapy, 2011, 29, 197-200.	0.6	14
166	Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11â€“13 Weeks?. Fetal Diagnosis and Therapy, 2011, 30, 53-59.	0.6	8
167	Normal Range of Maternal Serum Vitamin D at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2011, 30, 94-99.	0.6	12
168	Maternal Serum Î±-Fetoprotein at 11â€“13 Weeksâ€™ Gestation in Spontaneous Early Preterm Delivery. Fetal Diagnosis and Therapy, 2011, 30, 88-93.	0.6	29
169	Maternal Plasma Plasminogen Activator Inhibitor-2 at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Hypertension in Pregnancy, 2011, 30, 194-202.	0.5	6
170	Maternal Plasma P-selectin at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Hypertension in Pregnancy, 2011, 30, 311-321.	0.5	10
171	Maternal Serum Alpha-Fetoprotein in Normal Pregnancy at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2011, 30, 274-279.	0.6	15
172	Fetal RHD Genotyping in Maternal Plasma at 11â€“13 Weeks of Gestation. Fetal Diagnosis and Therapy, 2011, 29, 301-306.	0.6	53
173	Assisted conception and placental perfusion assessed by uterine artery Doppler at 11-13 weeks' gestation. Human Reproduction, 2011, 26, 1659-1664.	0.4	31
174	Placental Volume at 11â€“13 Weeksâ€™ Gestation in the Prediction of Birth Weight Percentile. Fetal Diagnosis and Therapy, 2011, 30, 23-28.	0.6	72
175	Maternal Serum Human Placental Growth Hormone (hPGH) at 11 to 13 Weeks of Gestation in Preeclampsia. Hypertension in Pregnancy, 2011, 30, 74-82.	0.5	11
176	Maternal and neonatal outcomes following Kielland's rotational forceps delivery. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, Fa9-Fa9.	1.4	3
177	Maternal plasma soluble fmsâ€like tyrosine kinaseâ€1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenatal Diagnosis, 2010, 30, 191-197.	1.1	48
178	Maternal serum insulinâ€like growth factorâ€I at 11â€“13 weeks in preeclampsia. Prenatal Diagnosis, 2010, 30, 1026-1031.	1.1	26
179	Fetal sex determination using circulating cellâ€free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation. Prenatal Diagnosis, 2010, 30, 918-923.	1.1	38
180	Maternal Serum Placental Protein 13 at Eleven to Thirteen Weeks in Chromosomally Abnormal Pregnancies. Fetal Diagnosis and Therapy, 2010, 27, 72-77.	0.6	7

#	Article	IF	Citations
181	Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Ligation for Noninvasive Prenatal Diagnosis of Trisomy 21. Clinical Chemistry, 2010, 56, 459-463.	1.5	125
182	Effect of Chorionic Villus Sampling on Uterine Artery Doppler. Fetal Diagnosis and Therapy, 2010, 28, 9-13.	0.6	5
183	Maternal Thyroid Function at 11â€“13 Weeks of Gestation. Fetal Diagnosis and Therapy, 2010, 27, 156-163.	0.6	38
184	Synergy of Total PLAC4 RNA Concentration and Measurement of the RNA Single-Nucleotide Polymorphism Allelic Ratio for the Noninvasive Prenatal Detection of Trisomy 21. Clinical Chemistry, 2010, 56, 73-81.	1.5	57
185	Chorionic Villus Sampling at 11 to 13 Weeks of Gestation and Hypertensive Disorders in Pregnancy. Obstetrics and Gynecology, 2010, 116, 374-380.	1.2	12
186	Epigenetic-Genetic Chromosome Dosage Approach for Fetal Trisomy 21 Detection Using an Autosomal Genetic Reference Marker. PLoS ONE, 2010, 5, e15244.	1.1	33
187	Systematic Identification of Placental Epigenetic Signatures for the Noninvasive Prenatal Detection of Edwards Syndrome. PLoS ONE, 2010, 5, e15069.	1.1	25
188	Multiplex ligation-dependent probe amplification: a reliable and cost efficient 'single-test' alternative for fetal chromosome analysis?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, Fa17-Fa18.	1.4	0
189	Maternal Serum Activin A at 11–13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Fetal Diagnosis and Therapy, 2009, 25, 320-327.	0.6	35
190	Maternal plasma inhibin A at 11â€“13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis, 2009, 29, 753-760.	1.1	61
191	Maternal serum angiopoietinâ€2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis, 2009, 29, 847-851.	1.1	9
192	Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis, 2009, 29, 934-938.	1.1	38
193	Maternal serum placental protein 13 at 11â€“13 weeks of gestation in preeclampsia. Prenatal Diagnosis, 2009, 29, 1103-1108.	1.1	97
194	First trimester urinary placental growth factor and development of preâ€eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 643-647.	1.1	27
195	First-Trimester Prediction of Hypertensive Disorders in Pregnancy. Hypertension, 2009, 53, 812-818.	1.3	389
196	Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2008, 32, 732-739.	0.9	222
197	Comparison of closure of subcutaneous tissue versus non-closure in relation to wound disruption after abdominal hysterectomy in obese patients. Journal of Postgraduate Medicine, 2000, 46, 26-8.	0.2	19
198	Rupture of left horn of bicornuate uterus at twenty weeks of gestation. Journal of Postgraduate Medicine, 2000, 46, 39-40.	0.2	11